Cargando…
PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429554/ http://dx.doi.org/10.1097/01.HS9.0000975336.52123.51 |
| _version_ | 1785090743792041984 |
|---|---|
| author | Ferreri, Christopher J. Quatela, Steven Aina, Oluwaseun Roy, Pourab Boyapati, Anita Lorenc, Karen Rodriguez Kroog, Glenn Orlowski, Robert Z |
| author_facet | Ferreri, Christopher J. Quatela, Steven Aina, Oluwaseun Roy, Pourab Boyapati, Anita Lorenc, Karen Rodriguez Kroog, Glenn Orlowski, Robert Z |
| author_sort | Ferreri, Christopher J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429554 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104295542023-08-17 PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA Ferreri, Christopher J. Quatela, Steven Aina, Oluwaseun Roy, Pourab Boyapati, Anita Lorenc, Karen Rodriguez Kroog, Glenn Orlowski, Robert Z Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429554/ http://dx.doi.org/10.1097/01.HS9.0000975336.52123.51 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Ferreri, Christopher J. Quatela, Steven Aina, Oluwaseun Roy, Pourab Boyapati, Anita Lorenc, Karen Rodriguez Kroog, Glenn Orlowski, Robert Z PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA |
| title | PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA |
| title_full | PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA |
| title_fullStr | PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA |
| title_full_unstemmed | PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA |
| title_short | PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA |
| title_sort | pb2144: trial in progress: a phase 1/2 window of opportunity study of the bcmaxcd3 bispecific antibody linvoseltamab in previously untreated patients with symptomatic multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429554/ http://dx.doi.org/10.1097/01.HS9.0000975336.52123.51 |
| work_keys_str_mv | AT ferrerichristopherj pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT quatelasteven pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT ainaoluwaseun pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT roypourab pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT boyapatianita pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT lorenckarenrodriguez pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT kroogglenn pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma AT orlowskirobertz pb2144trialinprogressaphase12windowofopportunitystudyofthebcmaxcd3bispecificantibodylinvoseltamabinpreviouslyuntreatedpatientswithsymptomaticmultiplemyeloma |